{"id":"https://openalex.org/W2043977360","doi":"https://doi.org/10.1592/phco.26.12.1694","title":"Pharmacoeconomic Evaluation of Antimuscarinic Agents for the Treatment of Overactive Bladder","display_name":"Pharmacoeconomic Evaluation of Antimuscarinic Agents for the Treatment of Overactive Bladder","publication_year":2006,"publication_date":"2006-11-27","ids":{"openalex":"https://openalex.org/W2043977360","doi":"https://doi.org/10.1592/phco.26.12.1694","mag":"2043977360","pmid":"https://pubmed.ncbi.nlm.nih.gov/17125433"},"language":"en","primary_location":{"id":"doi:10.1592/phco.26.12.1694","doi":"https://doi.org/10.1592/phco.26.12.1694","is_oa":false,"landing_page_url":"https://doi.org/10.1592/phco.26.12.1694","pdf_url":null,"source":{"id":"https://openalex.org/S122731057","display_name":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","issn_l":"0277-0008","issn":["0277-0008","1875-9114"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103046748","display_name":"Yu Mi Ko","orcid":"https://orcid.org/0000-0002-0187-1524","observed_orcids":["https://orcid.org/0000-0002-0187-1524"]},"institutions":[{"id":"https://openalex.org/I138006243","display_name":"University of Arizona","ror":"https://ror.org/03m2x1q45","country_code":"US","type":"education","lineage":["https://openalex.org/I138006243"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Yu Ko","raw_affiliation_strings":["Department of Pharmaceutical Sciences, College of Pharmacy, University of Arizona, Tucson, Arizona 85721-0207, USA. ko@pharmacy.arizona.edu","Department of Pharmaceutical Sciences and the Center for Health Outcomes and Pharmacoeconomic Research, College of Pharmacy, University of Arizona, Tucson, Arizona"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, College of Pharmacy, University of Arizona, Tucson, Arizona 85721-0207, USA. ko@pharmacy.arizona.edu","institution_ids":["https://openalex.org/I138006243"]},{"raw_affiliation_string":"Department of Pharmaceutical Sciences and the Center for Health Outcomes and Pharmacoeconomic Research, College of Pharmacy, University of Arizona, Tucson, Arizona","institution_ids":["https://openalex.org/I138006243"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067710734","display_name":"Daniel C. Malone","orcid":"https://orcid.org/0000-0002-5006-9394","observed_orcids":["https://orcid.org/0000-0002-5006-9394"]},"institutions":[{"id":"https://openalex.org/I138006243","display_name":"University of Arizona","ror":"https://ror.org/03m2x1q45","country_code":"US","type":"education","lineage":["https://openalex.org/I138006243"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel C. Malone","raw_affiliation_strings":["Center for Health Outcomes and Pharmacoeconomic Research, College of Pharmacy, University of Arizona, Tucson, Arizona"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Health Outcomes and Pharmacoeconomic Research, College of Pharmacy, University of Arizona, Tucson, Arizona","institution_ids":["https://openalex.org/I138006243"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015882459","display_name":"Edward P. Armstrong","orcid":"https://orcid.org/0000-0003-4147-3384","observed_orcids":["https://orcid.org/0000-0003-4147-3384"]},"institutions":[{"id":"https://openalex.org/I138006243","display_name":"University of Arizona","ror":"https://ror.org/03m2x1q45","country_code":"US","type":"education","lineage":["https://openalex.org/I138006243"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edward P. Armstrong","raw_affiliation_strings":["Center for Health Outcomes and Pharmacoeconomic Research, College of Pharmacy, University of Arizona, Tucson, Arizona"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Health Outcomes and Pharmacoeconomic Research, College of Pharmacy, University of Arizona, Tucson, Arizona","institution_ids":["https://openalex.org/I138006243"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5103046748"],"corresponding_institution_ids":["https://openalex.org/I138006243"],"apc_list":{"value":4030,"currency":"USD","value_usd":4030},"apc_paid":null,"fwci":3.5075,"has_fulltext":false,"cited_by_count":65,"citation_normalized_percentile":{"value":0.91209856,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"26","issue":"12","first_page":"1694","last_page":"1702"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10279","display_name":"Urinary Bladder and Prostate Research","score":0.9750999808311462,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10279","display_name":"Urinary Bladder and Prostate Research","score":0.9750999808311462,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.014600000344216824,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10418","display_name":"Pelvic floor disorders treatments","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/overactive-bladder","display_name":"overactive bladder","score":0.996999979019165},{"id":"https://openalex.org/keywords/antimuscarinic-agents","display_name":"antimuscarinic agents","score":0.9950000047683716},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9639999866485596},{"id":"https://openalex.org/keywords/solifenacin","display_name":"solifenacin","score":0.9729999899864197},{"id":"https://openalex.org/keywords/oxybutynin","display_name":"oxybutynin","score":0.921999990940094},{"id":"https://openalex.org/keywords/tolterodine","display_name":"tolterodine","score":0.9810000061988831},{"id":"https://openalex.org/keywords/darifenacin","display_name":"darifenacin","score":0.9490000009536743},{"id":"https://openalex.org/keywords/trospium","display_name":"trospium","score":0.7960000038146973},{"id":"https://openalex.org/keywords/urinary-tract-infection","display_name":"urinary tract infection","score":0.8370000123977661},{"id":"https://openalex.org/keywords/drug-costs","display_name":"drug costs","score":0.6010000109672546},{"id":"https://openalex.org/keywords/continence","display_name":"continence","score":0.46799999475479126},{"id":"https://openalex.org/keywords/decision-analytic-model","display_name":"decision-analytic model","score":0.375}],"concepts":[{"id":"https://openalex.org/C2778941218","wikidata":"https://www.wikidata.org/wiki/Q331231","display_name":"Overactive bladder","level":3,"score":0.9302490949630737},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.6151535511016846},{"id":"https://openalex.org/C2781020410","wikidata":"https://www.wikidata.org/wiki/Q424312","display_name":"Tolterodine","level":4,"score":0.6051819324493408},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.505029022693634},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.06319394707679749},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003661","descriptor_name":"Decision Support Techniques","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D003661","descriptor_name":"Decision Support Techniques","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D003661","descriptor_name":"Decision Support Techniques","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D004304","descriptor_name":"Dosage Forms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004304","descriptor_name":"Dosage Forms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004304","descriptor_name":"Dosage Forms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014549","descriptor_name":"Urinary Incontinence","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D014549","descriptor_name":"Urinary Incontinence","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D014549","descriptor_name":"Urinary Incontinence","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018727","descriptor_name":"Muscarinic Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018727","descriptor_name":"Muscarinic Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018727","descriptor_name":"Muscarinic Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018727","descriptor_name":"Muscarinic Antagonists","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D018727","descriptor_name":"Muscarinic Antagonists","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D018727","descriptor_name":"Muscarinic Antagonists","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D018727","descriptor_name":"Muscarinic Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018727","descriptor_name":"Muscarinic Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018727","descriptor_name":"Muscarinic Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D053201","descriptor_name":"Urinary Bladder, Overactive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D053201","descriptor_name":"Urinary Bladder, Overactive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D053201","descriptor_name":"Urinary Bladder, Overactive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1592/phco.26.12.1694","doi":"https://doi.org/10.1592/phco.26.12.1694","is_oa":false,"landing_page_url":"https://doi.org/10.1592/phco.26.12.1694","pdf_url":null,"source":{"id":"https://openalex.org/S122731057","display_name":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","issn_l":"0277-0008","issn":["0277-0008","1875-9114"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","raw_type":"journal-article"},{"id":"pmid:17125433","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17125433","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.6700000166893005}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":45,"referenced_works":["https://openalex.org/W1558658318","https://openalex.org/W1965460248","https://openalex.org/W1967327049","https://openalex.org/W1968860914","https://openalex.org/W1973445202","https://openalex.org/W1974084711","https://openalex.org/W1975485647","https://openalex.org/W1976101513","https://openalex.org/W1976233624","https://openalex.org/W1994653403","https://openalex.org/W2005182544","https://openalex.org/W2006965427","https://openalex.org/W2008079238","https://openalex.org/W2012563222","https://openalex.org/W2012729846","https://openalex.org/W2014075072","https://openalex.org/W2019362433","https://openalex.org/W2021702941","https://openalex.org/W2023548731","https://openalex.org/W2024975356","https://openalex.org/W2026599479","https://openalex.org/W2033133691","https://openalex.org/W2034782018","https://openalex.org/W2044943786","https://openalex.org/W2056759810","https://openalex.org/W2063920892","https://openalex.org/W2067886717","https://openalex.org/W2069015817","https://openalex.org/W2070661957","https://openalex.org/W2083510953","https://openalex.org/W2086940332","https://openalex.org/W2088679190","https://openalex.org/W2092749677","https://openalex.org/W2094952568","https://openalex.org/W2115070503","https://openalex.org/W2123887587","https://openalex.org/W2131173377","https://openalex.org/W2136398611","https://openalex.org/W2141398206","https://openalex.org/W2148524234","https://openalex.org/W2148567690","https://openalex.org/W2153390278","https://openalex.org/W2315116932","https://openalex.org/W2396706702","https://openalex.org/W4246953292"],"related_works":["https://openalex.org/W2079287622","https://openalex.org/W2399603275","https://openalex.org/W2109858998","https://openalex.org/W2072244742","https://openalex.org/W4249422538","https://openalex.org/W2962813502","https://openalex.org/W2544346309","https://openalex.org/W1587585344","https://openalex.org/W2068095285","https://openalex.org/W2096360296"],"abstract_inverted_index":{"STUDY":[0],"OBJECTIVE:":[1],"To":[2],"compare":[3],"the":[4,11,76,104,128,187,191,203,210],"cost-effectiveness":[5],"of":[6,13,44,212],"various":[7,196],"antimuscarinic":[8,78,172,197],"agents":[9,173],"for":[10,40,98,127,136,165],"treatment":[12,32,43,162,211],"overactive":[14],"bladder":[15],"(OAB).":[16],"METHODS:":[17],"A":[18,63],"decision-analysis":[19],"model":[20,129],"was":[21,58,118,130,163],"developed":[22],"and":[23,38,42,53,91,95,106,160,181,206],"included":[24],"clinical":[25],"outcomes":[26],"(i.e.,":[27,47],"therapy":[28],"continued":[29,159],"or":[30,34],"discontinued,":[31],"success":[33,57],"failure,":[35],"OAB-induced":[36,45],"comorbidities)":[37],"costs":[39,108,135,180,205],"drugs":[41,100],"comorbidities":[46],"urinary":[48],"tract":[49],"infections,":[50],"fractures,":[51],"depression,":[52],"skin":[54],"infections).":[55],"Treatment":[56],"defined":[59],"as":[60],"complete":[61],"continence.":[62],"systematic":[64],"MEDLINE":[65],"literature":[66],"search":[67],"from":[68,103,120,142],"January":[69],"1990-January":[70],"2006":[71],"identified":[72],"English-language":[73],"articles":[74],"concerning":[75],"eight":[77],"drugs:":[79],"darifenacin,":[80],"solifenacin,":[81],"trospium,":[82],"immediate-release":[83,89,153],"oxybutynin,":[84,86,88],"extended-release":[85,92],"transdermal":[87],"tolterodine,":[90],"tolterodine.":[93],"Probabilities":[94],"cost":[96],"data":[97],"these":[99],"were":[101,109,176,186],"retrieved":[102],"literature,":[105],"drug":[107],"based":[110],"on":[111],"2005":[112],"average":[113,156],"wholesale":[114],"prices.":[115],"The":[116,124,155],"analysis":[117],"constructed":[119],"a":[121],"payer's":[122],"perspective.":[123],"time":[125],"frame":[126],"3":[131],"months.":[132],"RESULTS:":[133],"Expected":[134],"each":[137],"patient":[138],"with":[139,146,152,158,178],"OAB":[140],"ranged":[141],"$3373":[143],"when":[144,150],"treated":[145,151],"solifenacin":[147,166,199],"to":[148],"$3769":[149],"oxybutynin.":[154],"cost/patient":[157],"successful":[161],"lowest":[164,204],"($6863).":[167],"Solifenacin":[168],"dominated":[169],"all":[170],"other":[171],"because":[174],"they":[175],"associated":[177],"high":[179],"low":[182],"effectiveness.":[183],"Success":[184],"rates":[185],"key":[188],"parameters":[189],"driving":[190],"sensitivity":[192],"analysis.":[193],"CONCLUSION:":[194],"Among":[195],"agents,":[198],"5":[200],"mg":[201],"had":[202],"highest":[207],"effectiveness":[208],"in":[209],"OAB.":[213]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":8},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":5}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2016-06-24T00:00:00"}